Intrinsic Value of S&P & Nasdaq Contact Us

Soligenix, Inc. SNGX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
34/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Soligenix, Inc. (SNGX) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 5 Buy, 3 Hold.

Analysts estimate Earnings Per Share (EPS) of $-7.10 and revenue of $0.00B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-5.23 vs est $-7.10 (beat +26.3%). 2025: actual $-2.14 vs est $-2.15 (beat +0.5%). Analyst accuracy: 82%.

SNGX Analyst Ratings

Buy
8
Ratings
5 Buy
3 Hold
Based on 8 analysts giving stock ratings to Soligenix, Inc. in the past 3 months
Rating breakdown
Buy
5 63%
Hold
3 38%
63%
Buy
5 analysts
38%
Hold
3 analysts
0%
Sell
0 analysts

EPS Estimates — SNGX

82%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual –$5.23 vs Est –$7.10 ▲ 35.8% off
2025 Actual –$2.14 vs Est –$2.15 ▲ 0.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.

Revenue Estimates — SNGX

0%
Analyst Accuracy
Inaccurate
1 year compared
Actual vs Estimate
2024 Actual $0.000B vs Est $0.001B ▼ 334.8% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message